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Effect of rifampicin & isoniazid on cytochrome P-450 in 
mycobacteria 
Geetha Ramachandran & Prema Gurumurthy 
Background & objectives: Rifampicin and isoniazid are the most important first line drugs used in the 
treatment of tuberculosis. These drugs are also used i n  combination with other medications to treat 
co-infections. It, therefore, becomes important to study the effect of these drugs on the drug 
metabolizing system, namely, cytochrome P-450, not only in the host but also in the bacteria. We 
report the effect of rifampicin and isoniazid on the cytochrome P-450 activity in Mycobacterium 
smegmatis and M tuberculosis H37Rv. 
Methods: Subinhibitory concentrations of rifampicin and isoniazid were added to the organisms after 
they had attained the growth phase and cytochrome P-450 activity was estimated in the membranous 
fractions of the bacteria at different time points. 
Results: Rifampicin was able to significantly enhance cytochrome P-450 in both M. smegmatis and 
M. tuberculosis H37Rv. Isoniazid was found to inhibit cytochrome P-450 in M. tuberculosis H37Rv, While 
there seemed to be no effect in M. smegmatis. 
Interpretation & conslusion: We report here the effect of rifampicin and isoniazid on mycobacterial 
cytochrome P-450. These findings are similar to those found in eukaryotic organisms. The role of 
mycobacterial cytochrome P-450 i n  the metabolism of drugs within the bacteria needs to be elucidated. 
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Standard short course regimens for tuberculosis 
are used world-wide. Unfortunately, the emergence 
of multiple drug - resistant tuberculosis in many 
parts of the world is leading to a diversification of 
drug regimens and to the use of drugs that are more 
toxic per se and more likely to interact with other 
drugs. The mechanisms by which antimicrobial 
agents alter the biotransformation of other drugs is 
increasingly understood to reflect inhibition or 
induction of specific cytochrome P-450 enzymes1. 
The Cytochrome P-450 group of proteins function 
as terminal monooxygenases in the microsomal 
mixed function oxidase system and bring about 
biotransformation and detoxification of a wide 
variety of drugs. 
Rifampicin (RMP) is usually administered for 
4 to 6 months with other anti-tuberculosis drugs or 
medications from other classes. A potential for drug 
interactions often exists because RMP is a potent 
inducer of hepatic drug metabolism, as evidenced 
by a proliferation of smooth endoplasmic reticulum2 
and an increase in the Cytochrome P-450 content in 
the liver3. Rifampicin can therefore, reduce the 
efficacy of several therapeutically important drugs 
by accelerating systemic elimination or by increasing 
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hepatic metabolism. This may result in sub- 
therapeutic concentrations of the accompanying 
drugs and failure of therapy. 
Apart from treating tuberculosis, the use of  
isoniazid (INH) has increased over the past years, 
largely as  a result of the co-epidemic of HIV 
infection. Isoniazid is given to patients who are also 
prescribed other medications for critical illness. 
Although i t  has best been recognised as an inhibitor 
of drug metabolism. i t  has a biphasic effect of 
inhibition - induction on a particular cytochrome 
P-450 isozyme4. 
Most reports that have so far emerged on drug 
interactions involving RMP and INH and cytochrome 
P-450 are based on animal and human studies. 
However, the role of bacterial cytochrome P-450 
should not be ignored as the drugs act directly on 
the bacterial protein. We, therefore studied the 
in vitro effect of RMP and INH on cytochrome 
P-450 in M. tuberculosis H37Rv and a nontuberculous 
mycobacterial species, viz., M. smegmatis. 
Material & Methods 
Chemicals : R i fampicin , isoniazid, lysozyme, 
ß mercaptoethanol and phenyl methyl sulphonyl 
fluoride (PMSF), from Sigma Chemical Co., USA, 
and sodium dithionite from Riedel - DeHaan Ag, 
Hannover, were used in this study. All other 
chemicals used were of analytical grade. 
The effect of RMP and INH on the activity of 
cytochrome P-450 was analysed in M. smegmatis 
and M. tuberculosis H37Rv under in vitro conditions. 
The organisms were grown in Sauton's liquid 
medium at 37OC in an incubator shaker. When the 
bacteria had attained the growth phase, subinhibitory 
concentrations of RMP (12 µg/ml for M. smegmatis 
and 0.125 and 0.25 µg/ml for M. tuberculosis H37Rv) 
and INH (25 µg/ml for M. smegmatis and 0.05 and 
0.10 µg/ml for M. tuberculosis H37Rv) were added 
to separate flasks containing the medium with the 
organisms. Subinhibitory concentrations of the 
drugs were selected based on the minimum 
inhibitory concentration (MIC) of the drug against 
the two organisms. Stock solutions of the drugs were 
prepared under sterile conditions. Incubation of the 
flasks was continued at 37OC and the bacterial cells 
were harvested by centrifugation at the end of 1,3 
and 6 h. Organisms from the flasks not containing 
the drugs were processed simultaneously and served 
as control for both the drugs, for each organism and 
at all 3 time points. 
Preparation of membranous fraction of bacteria and 
estimation of cytochrome P-450 activity: As 
cytochrome P-450 is a membrane bound protein the 
membranous fraction of the bacteria was prepared 
and cytochrome P-450 activity was estimated 
according to the method standardized in our 
laboratory5. The activity of cytochrome P-450 was 
determined by suitably diluting the samples in 10 
m M potassium phosphate buffer, p H 7.4 followed 
by addition of sodium dithionite. The reduced 
protein was made to bind with carbon monoxide and 
the spectrum was recorded between 500 and 300 nm 
in a dual beam spectrophotometer. The cytochrome 
P-450 concentration was calculated by taking the 
difference in the optical density between 450 and 
490nm and using molar extinction coefficient of 9 1 
mm/cm and expressed as nmol/mg protein. Studies 
with RMP and INH in both the bacteria were done 3 
times, each in duplicate. 
Student's t-test (unpaired and paired) was used to 
calculate the significance of the results and the level 
of significance was taken at 5 per cent. 
Results 
The cytochrome P-450 activity in M. smegmatis 
following the addition of subinhibi tory  
concentrations of RMP and INH is shown in 
Table I. The cytochrome P-450 levels significantly 
(P<0.05) increased in the presence of 12.0 µg/ml of 
RMP at all 3 time points tested when compared with 
the corresponding control values. The difference in 
the cytochrome P-450 activity in the presence of 
RMP between first and third hour was significant 
(P<0. 0 5 ) . H ow ever, the activity increased only 
marginally at the sixth hour when compared to the 
third hour and this difference was not significant 
(P=0.103). In the case of INH, the cytochrome 
P-450 activity in M. smegmatis remained unaltered 
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even at 6 h. and was not significantly different from 
control values. 
The cytochrome P-450 activity obtained in 
M. tuberculosis H37Rv following the addition of 
0.125 and 0.25 µg/ml of  RMP and 0.05 and 
0.10 µg/ml INH is shown in Table 11. At both 
concentrations, RMP was able to significantly 
(P<0.001 ) induce cytochrome P-450 activity at the 
third and sixth hour, as compared to controls. 
However, the difference in the cytochrome P-450 
level at first hour between the control and drug 
treated bacteria was not Significant (P=0.202). 
Induction of cytochrome P-450 activity appeared to 
increase with increase in the concentration of RMP. 
Isoniazid (0.05 and 0.10 µg/ml) did not cause any 
significant change in the cytochrome P-450 activity 
in M. tuberculosis H37Rv at 1 and 3 h. However. at 
the sixth hour, both concentrations of the drug 
significantly (P<0.05) caused a lowering in the 
cytochrome P-450 levels, compared to controls. 
Increasing the concentration of INH did not cause 
any increase in the cytochrome P-450 activity. 
Discussion 
Drug interactions involving cytochrome P-450 
generally result from one of two processes viz., 
enzyme induction or inhibition. The inhibition of 
drug metabolism by competition for the same 
enzyme may result in an undesirable elevation in 
plasma drug concentrations. Enzyme induction on 
the other hand may result in a reduction in 
pharmacological effect because of increased drug 
metabolism. of 
cytochrome P-450 is of clinical importance for both 
therapeutic and toxicological reasons. In the safety 
evaluation of drugs and other chemicals. it is hence 
important to evaluate their possible inducing and 
inhibitory effects on the enzymes of drug 
metabolism. 
Thus  , induction / inhibition 
~~ ~~ ~~~ 
Table 1. Cytochrome P-450 levels (nmol/mg protein) in M. smegmatis after addition of R M P  and I N H  
Time after R M P  I N H  
incubation ( h )  
Control Test (12.0 µg/ml) Control Test (25.0µg/ml) 
I 0.39±0.06 0.57±0.10* 0.43±0.02 
3 0.27±0.03 0.72±0.01*† 0.36±0.04 0.4±0.04 
0 0.33±0.02 0.76±0.03*† 0.32±0.04 0.30±0.04 
The values are mean±SD of 6 experiments. * P<0.05 compared to control, †P<0.05 compared to 1h. R M P ,  rifampicin 
INH,  isoniazid 
Table I I .  Cytochrome P-450 levels (nmol/mg protein) i n  M. tuberculosis H37Rv after addition of R M P  and I N H  
Time after R M P  INH 
incubation 
( h )  Control Test I Test 2 Control Test I Test 2 
1 0.58±0.02 0.64±0.09 0.42±0.03 0.25±0.02 0.37±0.06 0.37±0.06 
(0.125 µg/ml) (0.25 µg/ml) (0.05 µg/ml) (0.10µg/ml) 
3 0.55±0.04 0.94±0.02* 1.22±0.18* 0.42±0.06 0.42±0.06 0.40±0.06 
6 0.58±0.01 0.84±0.09* 1.02±0.05* 0.27±0.06 0.18±0.05** 0.18±0.05** 
The values are mean±SD of 6 experiments. * P<0.001 compared to control, **P<0.05 compared to control, RMP, rifampicin; 
INH.  isoniazid 
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Based on the results obtained in this study, it 
appears that RMP is able to significantly induce 
cytochrome P-450 activity in M. smegmatis and 
M. tuberculosis H37Rv. This effect was felt at the 
third hour itself after exposure to the drug. It was 
further observed that RMP induction of cytochrome 
P-450 is dose dependent, a condition similar to that 
observed in other systems6. These results are in 
agreement with previous studies done in animals and 
humans2,3,6-8 
It, thus, becomes clear that when RMP is given 
along with drugs that are metabolised through the 
cytochrome P-450 system, it should be borne in mind 
that the therapeutic efficacy of such drugs may be 
lowered due to enhanced metabolism and clearance. 
This observation gains significance with the use of 
antiretroviral drugs along with RMP. Protease 
inhibitors undergo metabo1ism through the 
cytochrome P-450 pathway and RMP is likely to 
lower the bioavailability of these drugs9. 
The results of this study also demonstrate that 
INH inhibited cytochrome P-450 of M. tuberculosis 
H37Rv in vitro. There are some reports that have 
shown INH as an inducer of the hepatic microsomal 
enzyme system10. It is quite possible that a single 
substance can act both as an inducer or as an 
inhibitor of the monoxygenase system depending on 
the dose used11. Oxidative metabolism represents a 
major route of elimination for many drugs and 
because many drugs can compete for the same 
enzyme. inhibition of cytochrome P-450 is one of 
the main reasons for drug interaction. The 
mechanism by which INH inhibits cytochrome 
P-450 could be due to the fact that the drug reaches 
a concentration that is critical for the formation of 
the catalytically inactive cytochrome P-450 - drug 
complex. Thus, when INH is given along with drugs 
that are metabolised through the cytochrome P-450 
system, it is essential to periodically monitor for 
toxic side effects arising due to decreased 
metabolism of the accompanying drugs. Inhibition 
of cytochrome P-450 can also reduce clinical 
efficacy if the drug is a prodrug requiring metabolic 
activation to achieve its effect and activation. 
Although RMP was able to significantly induce 
cytochorome P-450 in both M. smegmatis and 
M. tuberculosis H37Rv, INH could exert its 
inhibitory effect in only the latter. This selective 
inhibition could be due to poor penetration of the 
drug into M. smegmatis. 
The effects of RMP and INH on cytochrome 
P-450 of eukaryotic origin has been extensively 
reported. However, the effect of these drugs on the 
bacterial protein has not been looked into. This 
seems to be the first report on the effect of RMP 
and INH on cytochrome P-450 in mycobacteria. 
Although 22 genes coding for different isoforms of 
cytochrome P-450 have been identified in the 
M. tuberculosis genome12, the function of these 
genes have not been well understood. It is quite 
possible that the cytochrome P-450 present in 
M. tuberculosis also plays a role in bringing about 
metabolism of the drugs while they are within the 
bacteria. Studies at the molecular level are necessary 
to throw light on this aspect. 
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